Insulet (NASDAQ:PODD) Hits New 52-Week Low – Time to Sell?

Insulet Corporation (NASDAQ:PODD) reached a new 52-week low during trading on Wednesday . The company traded as low as $146.20 and last traded at $148.1310, with a volume of 569929 shares. The stock had previously closed at $158.35.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PODD shares. The Goldman Sachs Group set a $237.00 price objective on shares of Insulet in a report on Thursday, May 7th. Oppenheimer reduced their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Stifel Nicolaus decreased their price target on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Jefferies Financial Group lowered their price target on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Finally, Robert W. Baird dropped their price objective on Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Nineteen research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $257.09.

Insulet Stock Down 6.0%

The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market cap of $10.31 billion, a PE ratio of 34.61, a P/E/G ratio of 1.25 and a beta of 1.20. The business’s 50-day simple moving average is $205.63 and its 200 day simple moving average is $260.20.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s revenue was up 33.9% compared to the same quarter last year. During the same period last year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts expect that Insulet Corporation will post 6.44 earnings per share for the current year.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.36% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insulet

Large investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its position in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet during the fourth quarter valued at approximately $26,000. DV Equities LLC purchased a new stake in Insulet during the fourth quarter valued at approximately $28,000. Elyxium Wealth LLC acquired a new stake in Insulet in the fourth quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in Insulet in the fourth quarter valued at approximately $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.